SRPT Stock Cash Flow Statements

Sarepta Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Sarepta Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-07-22	2012-12-31	2012-07-22	2011-07-22	2011-03-31	2010-07-22	2008-06-30	2007-07-22	2006-07-22	2005-07-22	2004-03-31	2003-12-31	2003-07-22	2002-07-22	2001-12-31	2001-07-22

cash flows from operating activities:
net income	196,892,000	-447,508,000	159,049,000	33,611,000	6,460,000	36,119,000	45,655,000	-40,937,000	-23,940,000	-516,755,000	-109,244,000	-257,738,000	-231,481,000	-105,025,000	-121,981,000	-48,144,000	-81,405,000	-167,250,000	-189,317,000	-196,499,000	-150,820,000	-17,492,000	-235,703,000	-126,326,000	-276,403,000	-76,643,000	-140,895,000	-76,393,000	-109,267,000	-35,363,000	-23,998,000	-47,734,000	-63,046,000	84,090,000	-88,452,000	-56,742,000	-62,301,000	-59,770,000	-64,681,000	-51,939,000	-41,851,000	-61,559,000	-44,416,000	-29,226,000	-33,874,000	-28,273,000	-440,071,000	-42,084,000	-372,031,000	-17,704,000	308,925,000	-305,813,000	-584,000	-7,042,123	-9,722,975	-9,061,150	-5,499,179	-7,532,512	113,481,830	-3,418,817	-95,035,100	-64,898,088	-63,472,543
stock-based compensation	37,025,000	41,428,000	49,676,000	43,450,000	50,482,000	40,692,000	45,826,000	48,061,000	47,377,000	41,250,000	50,510,000	50,418,000	102,892,000	29,198,000	29,782,000	26,684,000	28,969,000	28,508,000	29,527,000	26,903,000	27,616,000	24,024,000	22,064,000	20,637,000	19,762,000	16,139,000	12,838,000	11,484,000	15,279,000	10,526,000	7,366,000	6,922,000	10,465,000	5,712,000	6,869,000	9,428,000	6,830,000	6,835,000	6,348,000	5,683,000	5,930,000	14,156,000	5,767,000	4,649,000	5,587,000	4,342,000	35,724,000	1,671,000	30,233,000	708,000	-25,149,000	27,011,000	426,000	-260,433	2,360,770	1,937,271
gain on strategic investments	-36,721,000	90,728,000
depreciation and amortization	10,840,000	9,978,000	10,455,000	9,806,000	8,719,000	8,744,000	11,372,000	10,928,000	10,792,000	11,305,000	10,553,000	10,703,000	9,889,000	10,719,000	10,145,000	10,495,000	8,447,000	8,930,000	7,288,000	6,619,000	6,475,000	6,529,000	8,206,000	8,277,000	7,694,000	6,370,000	3,527,000	3,593,000	2,873,000	2,252,000	2,124,000	2,559,000	1,772,000	1,637,000	1,664,000	1,074,000	1,476,000	1,397,000	1,364,000	1,312,000	1,291,000	1,280,000	1,158,000	1,049,000	960,000	523,000	22,249,000	451,000	20,880,000	353,000	-18,894,000	19,384,000	347,000	217,496	479,630	525,141	484,038	428,274	-4,903,656	333,186	4,292,464	3,706,574	3,563,080
reduction in the carrying amounts of the right of use assets	4,022,000	3,934,000	3,878,000	4,325,000	4,012,000	3,952,000	3,859,000	3,825,000	3,593,000	3,218,000	3,553,000	3,668,000	1,859,000	3,655,000	1,213,000	4,089,000	3,803,000	2,220,000		3,360,000	3,236,000	2,153,000
accretion of investment discount	-1,866,000	-1,912,000	-6,803,000	-10,615,000	-10,458,000	-12,401,000	-13,329,000	-12,602,000	-11,594,000	-8,651,000
non-cash change in the fair value of derivatives			-727,000
other	1,611,000	1,692,000	308,000	2,889,000	-1,396,000	329,000	-1,487,000	2,001,000	-2,441,000	1,964,000	-5,785,000	-2,867,000	-2,829,000	1,838,000	3,656,000	178,000	1,012,000	2,774,000	-545,000	875,000	581,000	-1,381,000	-202,000	0
changes in operating assets and liabilities, net:
decrease in accounts receivable
decrease (increase) in manufacturing-related deposits and prepaids	-2,267,000	71,136,000
increase in inventory	-59,189,000	-177,359,000	-161,659,000
increase in other assets	-22,191,000	-15,067,000	29,704,000
decrease in deferred revenue	25,572,000	-85,397,000	3,255,000
decrease in accounts payable, accrued expenses, lease liabilities and other liabilities	-24,467,000	-17,707,000
net cash from operating activities	261,337,000	-583,437,000	92,046,000	-70,699,000	14,942,000	-242,076,000	-54,657,000	-114,706,000	-122,234,000	-209,396,000	-92,392,000	-64,964,000	-66,815,000	-101,175,000	-29,326,000	-124,329,000	-109,146,000	-180,371,000	-174,535,000	-238,186,000	-107,603,000	627,790,000		-67,431,000	-79,004,000	-146,233,000		-113,318,000	-117,254,000	-35,668,000		-57,903,000	-85,147,000	-57,888,000		-60,615,000	-43,284,000	-60,688,000				-43,348,000	-25,449,000	-35,321,000	-39,504,000	-28,265,000	-277,730,000	-14,993,000	-237,372,000	-9,049,000	206,093,000	-216,601,000											-38,669,218
capex	-31,796,000	-43,651,000	-38,082,000	-37,263,000	-29,167,000	-32,444,000	-19,039,000	-29,673,000	-17,909,000	-9,485,000	-7,964,000	-8,231,000	-9,078,000	-5,551,000	-2,206,000	-9,241,000	-5,894,000	-21,149,000	-28,610,000	-25,303,000	-19,169,000	-9,120,000		-9,429,000	-16,682,000	-16,263,000		-20,091,000	-8,697,000	-12,166,000		-765,000	-2,871,000	-4,465,000		-840,000	-419,000	-1,168,000				-532,000	-3,139,000	-12,464,000	-4,515,000	-5,326,000	-20,595,000	-9,000	-19,879,000	-9,000	18,252,000	-18,928,000											-4,814,759
free cash flows	229,541,000	-627,088,000	53,964,000	-107,962,000	-14,225,000	-274,520,000	-73,696,000	-144,379,000	-140,143,000	-218,881,000	-100,356,000	-73,195,000	-75,893,000	-106,726,000	-31,532,000	-133,570,000	-115,040,000	-201,520,000	-203,145,000	-263,489,000	-126,772,000	618,670,000		-76,860,000	-95,686,000	-162,496,000		-133,409,000	-125,951,000	-47,834,000		-58,668,000	-88,018,000	-62,353,000		-61,455,000	-43,703,000	-61,856,000				-43,880,000	-28,588,000	-47,785,000	-44,019,000	-33,591,000	-298,325,000	-15,002,000	-257,251,000	-9,058,000	224,345,000	-235,529,000											-43,483,977
cash flows from investing activities:
purchase of property and equipment	-31,796,000	-43,651,000	-38,082,000	-37,263,000	-29,167,000	-32,444,000	-19,039,000	-29,673,000	-17,909,000	-9,485,000	-7,964,000	-8,231,000	-9,078,000	-5,551,000	-2,206,000	-9,241,000	-5,894,000	-21,149,000	-28,610,000	-25,303,000	-19,169,000	-9,120,000	-17,257,000	-9,429,000	-16,682,000	-16,263,000	-20,203,000	-20,091,000	-8,697,000	-12,166,000	-3,899,000	-765,000	-2,871,000	-4,465,000	-2,914,000	-840,000	-419,000	-1,168,000	-1,085,000	-1,147,000	-637,000	-532,000	-3,139,000	-12,464,000	-4,515,000	-5,326,000	-20,595,000	-9,000	-19,879,000	-9,000	18,252,000	-18,928,000											-4,814,759
purchase of available-for-sale securities	0	-44,658,000	-162,911,000	-389,402,000	-330,832,000	-216,450,000	-569,536,000	-645,605,000	-403,036,000	-426,763,000	-427,540,000	-371,714,000	-357,832,000	-779,770,000	0	1,000	0	-29,989,000	-435,877,000	-140,953,000	-391,301,000	-365,437,000	-209,407,000	-252,937,000	-236,807,000	-494,481,000	-520,216,000	-355,564,000	-204,309,000	-91,514,000	-489,172,000	0							-112,369,000	-1,000			-2,179,000	-45,573,000	-49,947,000	-176,669,000
maturity and sales of available-for-sale securities	68,626,000	40,758,000				477,690,000
purchase of intangible assets and other	-188,000	-2,238,000
acquisition of strategic investments
net cash from investing activities	32,211,000	-291,177,000	764,118,000	-128,825,000	-98,528,000	218,796,000	-64,358,000	-210,571,000	96,634,000	12,492,000	9,796,000	19,119,000	-289,991,000	-785,807,000	-2,577,000	20,265,000	321,059,000	156,666,000	-123,891,000	54,075,000	-34,225,000	-17,680,000		-17,959,000	152,373,000	135,231,000	-237,736,000	-63,400,000	-55,092,000	-14,260,000	-493,695,000	124,949,000	-20,054,000	209,985,000	-198,774,000	10,224,000	78,935,000	19,422,000	-69,819,000	31,019,000	3,383,000	43,827,000	46,677,000	-20,541,000	-2,877,000	-182,289,000	-28,996,000	-7,720,000	-27,452,000	-262,000	23,859,000	-25,060,000			299,732					3,108,743			-8,641,093
cash flows from financing activities:
proceeds from exercise of stock options and purchase of stock under the employee stock purchase program	1,500,000	15,681,000	3,710,000	13,757,000	39,918,000	22,140,000	1,943,000	15,405,000	5,861,000	28,037,000	11,303,000	13,411,000	339,000	4,990,000	2,148,000	5,902,000	3,526,000	9,226,000	35,826,000	18,789,000	21,860,000	7,482,000		5,181,000	7,092,000	12,299,000
repurchases of common stock
payments related to revolving credit facility
net cash from financing activities	-23,817,000	12,471,000	48,991,000	13,757,000	39,918,000	22,140,000	1,943,000	15,405,000	5,861,000	101,795,000	10,749,000	216,429,000	339,000	4,990,000	549,248,000	5,902,000	3,526,000	2,893,000	326,937,000	18,789,000	17,575,000	319,022,000	256,966,000	1,733,000	6,292,000	377,563,000	521,283,000	-23,955,000	25,351,000	7,471,000	506,813,000	382,237,000	-1,174,000	206,000	7,287,000	333,712,000	38,167,000	-1,037,000	125,576,000	1,576,000	20,250,000	406,000	24,000	5,407,000	96,034,000	2,690,000	477,708,000	2,971,000	454,402,000	-20,000	-232,636,000	264,944,000				7,971,098	22,311,475	6,985,851	-88,087,728	26,152	101,657,406	69,509,268	69,312,047
decrease in cash, cash equivalents and restricted cash	269,731,000	-862,143,000		-185,767,000	-43,668,000	-1,140,000		-309,872,000	-19,739,000	-95,109,000				-881,992,000
cash, cash equivalents and restricted cash:
beginning of period	0	1,118,589,000		0	0	444,009,000		0	0	985,801,000		0	0	2,125,523,000		0	0	1,511,713,000		0	0	843,645,000	0	0	0	370,829,000	0	0	0	599,827,000	0	0	0	122,556,000	0	0	0	80,304,000	0	0	0	73,551,000	0	0	0	256,965,000		187,661,000		39,904,000			48,275,000	4,643,361	20,159,201	34,597,734	16,654,829	12,524,915		10,384,963
end of period	269,731,000	256,446,000		-185,767,000	-43,668,000	442,869,000		-309,872,000	-19,739,000	890,692,000		170,584,000	-356,467,000	1,243,531,000		-98,162,000	215,439,000	1,490,901,000		-165,322,000	-124,253,000	1,772,777,000	110,251,000	-83,657,000	79,661,000	737,390,000	161,127,000	-200,673,000	-146,995,000	557,370,000	-17,940,000	449,283,000	-106,375,000	274,859,000	-272,720,000	283,321,000	73,818,000	38,001,000	24,485,000	-13,719,000	-4,898,000	74,436,000	21,252,000	-50,455,000	53,653,000	49,101,000	-16,679,000	167,919,000	149,674,000	30,573,000	30,905,000	23,283,000	41,438,000	3,544,559	14,964,915	36,867,301	34,356,842	8,687,362	5,994,891	7,171,723	29,885,643	-13,543,067	22,001,736
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	269,731,000	240,867,000	905,155,000	-185,767,000	-43,668,000	427,290,000	-113,502,000	-309,997,000	-19,739,000	871,668,000	-71,847,000	170,059,000	-365,312,000	1,233,877,000	516,756,000	-98,162,000	215,439,000	1,481,836,000	28,011,000	-165,322,000	-124,253,000	1,764,212,000	110,251,000	-83,762,000	76,401,000	732,190,000	161,127,000	-200,673,000
restricted cash in other assets	0	15,579,000	0	0	0	15,579,000	-3,570,000	125,000	0	19,024,000	0	525,000	8,845,000	9,654,000	589,000	0	0	9,065,000	500,000	0	0	8,565,000	0	105,000	3,260,000	5,200,000
total cash, cash equivalents and restricted cash	269,731,000	256,446,000	905,155,000	-185,767,000	-43,668,000	442,869,000	-117,072,000	-309,872,000	-19,739,000	890,692,000	-71,847,000	170,584,000	-356,467,000	1,243,531,000	517,345,000	-98,162,000	215,439,000	1,490,901,000	28,511,000	-165,322,000	-124,253,000	1,772,777,000	110,251,000	-83,657,000	79,661,000	737,390,000	161,127,000	-200,673,000
supplemental disclosure of cash flow information:
cash paid during the period for income taxes	19,258,000	835,000	10,973,000	3,624,000	7,081,000	909,000	5,512,000
cash paid during the period for interest	0	7,188,000	687,000	7,188,000	793,000	7,188,000	794,000	7,312,000	794,000	7,023,000	3,145,000	13,493,000	16,092,000	11,688,000	16,222,000	11,947,000	16,092,000	11,688,000	13,956,000	5,430,000	9,647,000	5,385,000	4,275,000	0			4,447,000	803,000	5,205,000	853,000	988,000	386,000	247,000	291,000	363,000	371,000	419,000	409,000	410,000	322,000	19,000	18,000		20,000	20,000	20,000		22,000
supplemental schedule of non-cash activities:
intangible assets and property and equipment included in accounts payable and accrued expenses	-2,759,000	29,225,000	8,899,000	3,358,000	7,554,000	22,929,000	17,280,000	-4,869,000	9,792,000	11,136,000	1,254,000	-240,000	1,336,000	4,415,000	-482,000	-3,116,000
capitalized stock-based compensation and depreciation as inventory	6,925,000	7,285,000	7,813,000	7,449,000	6,954,000	6,333,000
lease liabilities arising from obtaining right of use assets	0	5,232,000	14,994,000	18,349,000	1,743,000	275,000	357,000	3,971,000	75,595,000	280,000	27,725,000	874,000	7,301,000	4,106,000	77,000	2,566,000	9,681,000	901,000	21,680,000
common stock issued for conversion or exchange of 2024 notes			91,572,000	1,000
increase in accounts receivable		-57,383,000	-167,464,000
acquisition of strategic investment		-241,388,000
payments related to obtaining revolving credit facility		-3,210,000
non-cash interest expense			1,204,000	1,246,000			1,237,000	1,231,000			1,525,000	2,039,000	2,031,000	1,957,000	1,964,000	1,926,000	1,875,000	1,816,000	6,922,000	6,315,000	5,875,000	6,342,000	5,557,000	5,374,000	5,305,000	5,208,000	4,984,000	5,248,000	5,018,000	4,940,000													-19,000
non-cash termination charges			0
impairment of strategic investments
loss on debt extinguishment							0	0	0	387,329,000	0
gain from sale of priority review voucher							0	0														-108,069,000									0	0	0	-125,000,000
increase in manufacturing-related deposits and prepaids			46,956,000
increase in accounts payable, accrued expenses, lease liabilities and other liabilities
purchase of intangible assets			0	0	0	-10,000,000	0																-1,034,000	-594,000	-599,000	-855,000	-555,000	-1,077,000	-883,000	-673,000	-624,000	-6,990,000	-356,000	-1,245,000
proceeds from sale of priority review voucher							0	0																							0	0	0	125,000,000
settlement of capped call share options for 2024 notes
payment on maturity of 2024 notes
debt conversion costs for 2024 notes							0	0	0	-6,887,000
proceeds from 2027 notes offering, net of commissions											0
purchase of capped call share options for 2027 notes											0
debt issuance costs for 2027 notes											-554,000
repurchase of 2024 notes											0
repayment of principal amount due under 2019 term loan											0
payment on debt extinguishment of 2019 term loan											0
increase in cash and cash equivalents																											161,127,000	-200,673,000	-146,995,000	-42,457,000		449,283,000	-106,375,000	152,303,000	-272,720,000	283,321,000	73,818,000	-42,303,000				885,000	21,252,000			-207,864,000	170,982,000	-19,742,000	189,578,000	-9,331,000	-2,684,000	23,283,000				2,269,567	17,702,013		-4,390,072		29,885,643		22,001,736
beginning of year
end of year
lease liabilities terminated											0	0			20,166,000	0	0	19,967,000
maturity and sale of available-for-sale securities				297,840,000					415,624,000	448,834,000		399,571,000				30,000,000	226,000,000	210,000,000		221,000,000	376,980,000	250,000,000		245,001,000	579,017,000	646,830,000				90,093,000		132,704,000
partial settlement of capped call share options for 2024 notes							0	0	0	80,645,000	0
modification of 2017 capped calls
proceeds from exercise of stock options not yet received
adjustments to reconcile net income to cash flows from operating activities:
non-cash change in the fair value of contingent consideration					0	10,100,000
net decrease (increase) in accounts receivable					18,809,000	21,521,000																																					946,000
net increase in manufacturing-related deposits and prepaids					-58,298,000	-145,046,000
net increase in inventory					-102,460,000	-60,512,000	-94,104,000	-26,612,000	-26,692,000	-306,000	-8,880,000	-26,536,000	-10,677,000	-4,687,000	-27,264,000	-19,713,000	-28,423,000	-8,372,000	-11,843,000	-40,468,000	-6,482,000	-1,789,000	-5,019,000	-9,791,000	-16,102,000	-15,022,000	-9,629,000	-11,690,000	-4,751,000	-15,770,000		-22,939,000	-11,309,000	-17,632,000
net decrease in other assets								-6,004,000				3,477,000	17,520,000	13,401,000																4,672,000
net decrease in deferred revenue					10,036,000	-50,416,000	-20,078,000	-22,495,000	-22,250,000	-22,005,000		-22,495,000	-22,250,000	-22,005,000
net decrease in accounts payable, accrued expenses, lease liabilities and other liabilities					77,593,000	-92,843,000				-67,541,000				-5,022,000
net increase in other assets						-2,315,000				-29,996,000									-52,201,000	-69,818,000	-16,343,000	-27,966,000	-7,381,000	-7,002,000	-8,144,000	-79,564,000	-52,294,000	-54,478,000				1,966,000				-7,809,000	2,786,000	-3,180,000					-4,845,000
common stock issued for exchange of 2024 notes								0	0	693,377,000
adjustments to reconcile net income to cash flows in operating activities:
net increase in accounts receivable							-81,472,000	-82,047,000	-12,972,000	-9,208,000	-13,119,000	2,345,000	-25,660,000	-25,204,000	-3,203,000	-22,267,000	-9,317,000	-16,863,000	20,487,000	-17,799,000	2,847,000	-15,996,000	-22,847,000	-11,051,000	-6,471,000	-1,466,000	-443,000	-5,616,000	-3,137,000	-10,380,000		-6,960,000	-5,513,000	-7,050,000		-4,000	8,000	-13,000	-1,244,000
net increase in accounts payable, accrued expenses, lease liabilities and other liabilities							61,088,000	-17,554,000			12,878,000	53,195,000
taxes paid related to net share settlement of equity awards															-1,432,000	0	0	-6,333,000	0	0	0	-4,798,000	0	-3,448,000
proceeds from sales of common stock, net of offering costs																															0
impairment of equity investments
maturity of available-for-sale securities																																		80,000,000				21,000,000	44,085,000	43,204,000			48,314,000	37,930,000
supplemental schedule of non-cash investing and financing activities:
accrued debt issuance costs for 2027 notes
loss on disposal of assets											5,314,000	86,000														88,000	3,844,000	57,000	27,000	10,000	13,000																	196,000	2,454,000	65,000	-2,063,000	2,107,000	189,000	-53,059	53,498	164,253	1,028
supplemental schedule of non-cash investing activities and financing activities:
(gain) loss on contingent consideration															0
gain from sale of priority review voucher, net of commission															0	0				0
impairment of equity investment															0
net decrease (increase) in other assets															29,048,000	485,000	38,755,000	34,915,000																774,000					5,286,000	1,268,000	1,282,000	7,413,000
net increase in deferred revenue															-22,494,000	-22,495,000	-22,250,000	-22,005,000	-22,494,000	-22,561,000	-25,953,000	820,437,000
proceeds from sale of priority review voucher, net of commission															0	0				0	0	108,069,000
proceeds from 2019 term loan
debt issuance costs for 2019 term loan
proceeds from issuance of common stock to roche, net of offering costs																			0	0
shares withheld for tax included in accrued expenses																0
accrued debt issuance costs
gain on contingent consideration
increase in cash, cash equivalents and restricted cash												170,584,000				-98,162,000	215,439,000	-20,812,000		-165,322,000	-124,253,000	929,132,000		-83,657,000	79,661,000	366,561,000
acquired in-process research and development																							0	0																									29,461,000	0		29,461,000									19,545,028		19,545,028
non-cash up-front payment to stridebio
acquisition of myonexus therapeutics, inc., net of cash acquired																							0	0
proceeds from term loans
debt issuance costs
net increase in accounts payable, accrued expenses and other liabilities																-52,956,000				20,065,000	46,009,000	-57,718,000																					15,269,000			1,704,000
amortization of investment discount																	-19,000	-82,000	-80,000	-178,000	-644,000	-1,284,000	-996,000	-1,649,000	-2,324,000	-3,476,000		-1,914,000	-1,569,000	-1,259,000
net decrease in accounts payable, accrued expenses and other liabilities																		-44,962,000
intangible assets and property and equipment included in accrued expenses																		5,729,000	-3,141,000	-740,000	2,878,000	6,154,000
issuance costs related to the roche collaboration in accrued expenses																						4,285,000
loss on contingent consideration																			0
reduction in the carry amounts of the right of use assets
income from debt extinguishment
repayment of july 2017 term loan
proceeds from revolving line of credit																											18,150,000	44,368,000	77,119,000	96,235,000	15,708,000
repayment of revolving line of credit																											-17,323,000
payment for debt extinguishment
repayment of mortgage loans and notes payable
reclassification of long term investments to short term investments																											0	0	0	9,980,000
proceeds from sale of common stock, net of offering costs																								0	89,000	365,264,000
right of use asset and lease liability additions
sale of available-for-sale securities included in investment receivable																									-22,300,000	42,300,000
proceeds from issuance of common stock to roche																						316,338,000
manufacturing right of use asset additions																						27,554,000
manufacturing lease liability additions																						24,783,000
net cash from operations																																							-31,272,000	-46,314,000
purchase of restricted investment
maturity of restricted investment																															0	0	0	10,695,000
net cash provided (used) in investing activities
proceeds from exercise of options and employee stock purchase program
proceeds from december 2019 term loan
repayment of june 2015 and july 2017 term loan																											0
proceeds from july 2017 term loan
purchase of capped call options
proceeds from convertible debt offering
accrued debt discount and issuance costs
property and equipment included in accrued expenses																							-936,000	-785,000	24,000	2,878,000	2,906,000	2,226,000	-2,691,000	2,980,000	2,140,000			330,000			80,000	19,000	107,000			45,000	-888,000	743,000
net increase in accounts payable, accrued expenses, deferred revenue and other liabilities																								54,100,000			58,578,000	14,069,000	12,811,000	4,704,000											4,518,000	-5,084,000
purchases of restricted investment																												0
repayments on mortgage loans
payment of debt extinguishment
reclassification of revolving line of credit balance to other receivable
intangible assets included in accrued expenses																								-16,000	-4,000	230,000	140,000	-60,000	92,000	202,000	85,000	-7,000	86,000	179,000	-67,000
accrual for debt issuance costs related to the term loans
net decrease in accounts payable, accrued expenses, deferred revenue and other liabilities																										2,133,000								-886,000				-6,214,000
shares withheld for taxes																										889,000	8,000	3,303,000			436,000	1,482,000	144,000	165,000	213,000	1,851,000	60,000	44,000
amortization of investment (discount) premium
income from extinguishment of debt
non-cash restructuring expense
accrued exit and legal fees for debts
reclassification of software licenses																															0
property and equipment reclassified to asset held for sale																															0
proceeds from july 2017 term loan, net of cash debt issuance costs
asset held for sale
debt issuance costs related to the term loans included in accrued expenses
offering costs related to equity offerings included in accrued expenses
payments on mortgage loans																													0	-1,265,000
payments on revolving line of credit																													-73,511,000	-100,142,000
proceeds from exercise of options and purchase of stock under the employee stock purchase program																													21,743,000	12,643,000		7,693,000	1,337,000	2,749,000				1,488,000
repayments of long-term debt																																									-24,000	-25,000	-24,000	-23,000	-24,000	-23,000	-452,000	-22,000	-366,000	-21,000	244,000	-284,000
payment of term loan
(accretion of discount) amortization of premium on available-for-sale securities
increase in accounts payable, accrued expenses, deferred revenue and other liabilities
proceeds from term loan
payments of term loan and notes payable
payment of revolving line of credit
proceeds from exercise of options and warrants and employee stock purchase program
accrual for offering costs related to the equity offerings																																			-169,000
(accretion of discount) amortization of premium on available-for- sale securities and non-cash interest
non-cash restructuring expenses
proceeds from july 2017 term loan (defined in note 12), net of cash debt issuance costs
payments on june 2015 term loan (defined in note 12) and mortgage loans
accrual for offering costs related to equity offerings
amortization of (discount) premium on available-for-sale securities and non-cash interest																																	-125,000	-18,000
loss on abandonment of patents																																	119,000	485,000	248,000	21,000	9,000	15,000	17,000	48,000
repayments of long-term debt and notes payable																																	-2,511,000	-2,543,000	-2,527,000	-2,525,000	-26,000	-2,525,000	-25,000
accrual for debt issuance costs related to the senior secured term loan																																	0	400,000		0
accrual for senior secured term loan principal payment
accrual for offering costs related to the june 2016 equity offering
amortization of premium, net of discount, on available-for-sale securities and income from sales of available-for-sale securities
increase in warrant valuation																																														3,251,000
release and maturity of restricted investments																																											4,000,000	0
patent costs																																					-358,000	-410,000	-450,000	-342,000	-249,000	-391,000	-319,000	-434,000	-334,000	-294,000	-10,653,000	-461,000	-9,915,000	-253,000	7,949,000	-8,474,000											-1,696,468
proceeds from borrowings, net of debt issuance costs																																							0	-133,000
cash and cash equivalents:
accrued debt issuance costs related to the senior secured term loan																																							0
issuance of common stock in satisfaction of warrants
issuance of notes payable in relation to the purchase of certain real and personal property located in andover, massachusetts
amortization of premium on available-for-sale securities, income from sale of available-for-sale securities and non-cash interest																																				79,000
purchase of restricted investments																																							0								-90,000	-7,250,000
sale and maturity of available-for-sale securities																																				11,389,000
proceeds from sales of common stock
capitalized interest																																							0	0	0	99,000	101,000
proceeds from exercise of options, purchase of stock under the employee stock purchase program and sales of common stock
patent costs included in accrued expenses																																					67,000	192,000	230,000	-65,000	70,000	100,000
amortization of premium on available-for-sale securities and non-cash interest																																						242,000
amortization of premium on available-for-sale securities																																											615,000	690,000	608,000	519,000
non-cash interest
proceeds from exercise of options and warrants and the sale of common stock, net of offering costs																																							125,601,000	4,233,000			48,000	5,430,000
other financing activities																																															-434,000
tenant improvement paid by landlord
issuance of note payable in relation to the purchase of certain real and personal property located in andover, massachusetts
decrease in cash and cash equivalents																																								-13,719,000
accrued legal and other fees for the october 9, 2015 common stock offering
amortization of premium on available-for-sale securities and noncash interest
issuance of common stock in satisfaction of warrants and other liabilities																																											0	5,570,000	3,171,000	3,044,000		1,022,000
accrual for the debt issuance costs related to the senior secured term loan
adjustments to reconcile net income to net cash flows used in operating activities:
amortization of premium on available-for-sale securities and other non-cash interest expense																																										315,000
loss on abandonment of patents and disposal of property and equipment																																										131,000	76,000			6,000
sale of available-for-sale securities																																										44,750,000
proceeds from exercise of options and warrants																																										431,000
supplemental disclosure of cash flow information
supplemental schedule of noncash investing activities and financing activities:
tenant improvements paid by landlord																																											-1,000	89,000	-528,000	593,000	2,522,000
loss on change in warrant valuation																																											0	-4,256,000
cash paid during the year for interest																																																	510,000	22,000	-377,000	422,000	19,000
issuance of debt in relation to the purchase of certain real and personal property located in andover, massachusetts
net increase in accounts receivable and other assets																																													-10,620,000	-10,337,000		-1,178,000
receivable for warrants exercised
realized gain on sale of available-for-sale securities
write-down of available-for-sale securities
impairment charge on real estate owned																																																	1,445,000	0		1,336,000
acquisition costs																																																	-2,389,000	0		-2,389,000											-2,377,616
proceeds from exercise of options and warrants and the sale of common stock, warrants, and partnership units, net of offering costs																																														2,713,000
available-for-sale securities received in connection with the private offering
property and equipment included in accounts payable and other liabilities																																														3,533,000
issuance of common stock for building purchase																																																	750,000	0		750,000
assumption of long-term debt for building purchase																																																	2,200,000	0		2,200,000
issuance of common stock to acquire assets
assumption of liabilities to acquire assets																																																	2,124,000
realized gain on sale of short-term securities—available-for-sale																																																				-3,863,000
write-down of short-term securities—available-for-sale																																																	17,001,000			17,001,000
increase on warrant valuation
net increase in accounts receivable, other current assets and other assets																																															-5,440,000
net increase in accounts payable, accrued employee compensation, and other liabilities																																															20,014,000	-955,000			-1,229,000	11,326,000			1,195,910
purchase of marketable securities																																																	-112,993,000	0		-112,993,000
sale of marketable securities																																																	117,724,000	0		117,724,000			909,694	902,117	3,346,336	10,346,335	-5,463,808	4,989,198	2,696,377
proceeds from exercise of options and warrants, and the sale of common stock, warrants, and partnership units, net of offering costs
short-term securities—available-for-sale received in connection with the private offering																																																	17,897,000			17,897,000											17,897,000
loss on disposal of property and equipment
realized gain on sale of short-term securities — available-for-sale
write-down of short-term securities — available-for-sale
increase on warrant liability																																																		10,926,000
changes in operating assets and liabilities:
proceeds from sale of common stock, warrants, and partnership units, net of offering costs, and exercise of options and warrants																																																2,993,000	455,154,000	1,000	-233,266,000	265,614,000				7,971,098	22,311,475	6,985,851	-88,473,165	26,152	102,042,843	69,894,705	69,697,484
cash paid for interest
short-term securities — available-for-sale received in connection with the private offering
issuance of common stock in satisfaction of warrant liabilities
increase in warrant liability																																																26,906,000
short-term securities — available-for-sale received in connection with private offerings
issuance of common stock and warrants in satisfaction of liabilities																																																		0	-544,000	1,188,000
realized gain on sale of short-term securities— available-for-sale
conversion of interest accrued to common stock																																																		0		8,000									7,860		7,860
(increase) in accounts receivable, other current assets and other assets																																																		-1,830,000
increase in accounts payable, accrued employee compensation, and other liabilities																																																		-1,567,000
buyback of common stock pursuant to rescission offering																																																		0		-289,000											-288,795
withdrawal of partnership net assets																																																		0		-177,000											-176,642
issuance of convertible debt																																																		0		80,000									80,000		80,000
issuance of common stock to acuire assets
realized gain on sale of short-term securities - available-for-sale																																																		0
write-down of short-term securities - available-for-sale																																																		0
short-term securities - available-for-sale received in connection with the private offering																																																		0
issuance of common stock for ercole assets																																																		0		8,075,000
assumption of liabilities for ercole assets																																																		0		2,124,000
realized gain on sale of short-term securities–available-for-sale
write-down of short-term securities–available-for-sale
supplemental disclosure of cash flow
information:
short-term securities–available-for-sale received in connection with the private offering
increase in:
accounts receivable and other current assets																																																								281,612
change in unrealized gain on short-term securities—available-for-sale																																																							-2,041	1,890	132,641			-376,173
(gain) loss on warrant liability																																																				778,000
increase in accounts receivable, other current assets and other assets																																																				-15,337,000
write-down of short-term securities —available-for-sale
accounts receivable, other current assets, and other assets																																																					334,000
net increase in accounts payable, accrued employee compensation, deferred revenue, and other liabilities																																																					85,000
short-term securities —available-for-sale received in connection with the private offering
issuance of common stock and warrants to vendors
compensation expense on issuance of common stock and partnership units																																																													371,992		251,992
other assets																																																								2,900							-29,847
investment in other lt assets
issuance of common stock and warrants in satisfaction of employee bonuses
compensation expense to non-employees on issuance of options and warrants to purchase common stock or partnership units																																																						-195,802	312,637	525,126
gain on warrant liability
decrease (increase) in:
short-term securities—available-for-sale received in
connection with the private offering
change in unrealized gain on short-term
securities—available-for-sale
issuance of common stock to vendors																																																							300,000	700,000
issuance of common stock and warrants for services																																																								175,000					370,000	-120,000	240,000
compensation expense on issuance of options and warrants to purchase common stock or partnership units																																																									206,329	332,890	-359,147		682,353		562,353
related party receivables and other current assets																																																									399,958	43,738		239,677
net increase in accounts payable and accrued employee compensation																																																									28,316				4,839,853
write-down of short-term securities-available-for-sale																																																													12,523,088
other current assets																																																															-738,192
change in unrealized loss on short-term securities– available-for-sale																																																										-128,874
change in unrealized gain on short-term securities-available-for-sale
realized gain on sale of short-term securities
compensation expense on issuance of common
stock and partnership units
accounts payable and accrued employee compensation
short-term securities—available-for-sale received in connection with the private offering, related party
realized gain on sale of short-term investments — available for sale
proceeds from sale or redemption of short-term investments																																																													247,750		247,750
supplemental schedule of noncash investing
activities and financing activities:
short-term securities-available-for-sale received in connection with the private offering, related party																																																													17,897,000
change in unrealized gain on short-term securities— available-for-sale																																																													-2,852,652
realized gain on sale of short-term investments - available for sale																																																															-96,750
short-term securities — available-for-sale received in connection with the private offering, related party
change in unrealized gain on short-term securities — available-for-sale
write-down of short-term securities--available for sale
short-term securities--available-for-sale received in connection with the private offering, related party
change in unrealized gain on short-term securities--available-for-sale
net increase in accounts payable and accrued liabilities																																																															1,737,801
unrealized gain on short-term securities-- available-for-sale																																																															-13,278,794

We provide you with 20 years of cash flow statements for Sarepta Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sarepta Therapeutics stock. Explore the full financial landscape of Sarepta Therapeutics stock with our expertly curated income statements.

The information provided in this report about Sarepta Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.